CMA
VIR icon

Cedar Mountain Advisors’s Vir Biotechnology VIR Stock Holding History

Cedar Mountain Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03K Hold
101
– – ﹤0.01% 946
2026
Q1 		$905 Hold
101
– – ﹤0.01% 925
2025
Q4 		$609 Hold
101
– – ﹤0.01% 580
2025
Q3 		$577 Buy
+101
New +$516 ﹤0.01% 590

Other funds holding VIR

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FG
Foster Group West Des Moines, Iowa $3.76B AUM 21.29% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Cedar Mountain Advisors's VIR Position: Q2 2026 in Review

Cedar Mountain Advisors held its Vir Biotechnology (VIR) position steady in Q2 2026 at 101 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Cedar Mountain Advisors first reported a position in VIR in Q3 2025 and has held it in 4 quarters since. 14 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Cedar Mountain Advisors held 101 shares of Vir Biotechnology worth $1.03K as of Q2 2026.
  • Cedar Mountain Advisors left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #946 holding.
  • Cedar Mountain Advisors first reported a position in Vir Biotechnology in Q3 2025 and has held it in 4 quarters since.
  • 14 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.